| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -79,287 | -56,701 |
| Depreciation of property and equipment | 799 | 498 |
| Stock-based compensation | 7,189 | 5,077 |
| Amortization of premiums and accretion of discounts on marketable securities | 1,797 | 1,302 |
| Intangible asset amortization | 5,255 | 3,503 |
| Deferred income taxes | -21,743 | -15,769 |
| Other non-cash adjustments, net | -4,277 | -2,887 |
| Accounts receivable | 3,388 | -2,181 |
| Prepaid expenses and other assets | 6,123 | 6,826 |
| Inventory | 2,186 | 2,218 |
| Accounts payable and other liabilities | 6,743 | 16,966 |
| Product revenue allowances | 10,236 | 3,305 |
| Net cash used in operating activities | -80,025 | -48,399 |
| Asset acquisition | 0 | 0 |
| Purchases of property and equipment | 896 | 735 |
| Purchases of marketable securities | 110,347 | 96,300 |
| Sales and maturities of marketable securities | 161,237 | 125,667 |
| Net cash provided by (used in) investing activities | 49,994 | 28,632 |
| Principal payments on finance leases | 1,351 | 834 |
| Tax obligations paid in connection with settlement of restricted stock units | 915 | 915 |
| Net cash used in financing activities | -2,266 | -1,749 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | 3 | 183 |
| Net change in cash, cash equivalents and restricted cash | -32,294 | -21,333 |
| Cash and cash equivalents at beginning of period | 102,785 | - |
| Cash and cash equivalents at end of period | 70,491 | - |
Vanda Pharmaceuticals Inc. (VNDA)
Vanda Pharmaceuticals Inc. (VNDA)